Dorzolamide
Treatment for Glaucoma
Typical Dosage: One drop in affected eye(s) 2-3 times daily (2%)
Effectiveness
70%
Safety Score
70%
Clinical Trials
79
Participants
60K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
One drop in affected eye(s) 2-3 times daily (2%)
Time to Effect
30 minutes (maximal 2 hours)
Treatment Duration
Lifetime
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$540
Monitoring:$600
Side Effect Mgmt:$50
Total Annual:$1,190
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$1,983
Prescription Access Economics
Annual Societal Loss per Patient
$960
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$360/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$540/year
Potential OTC Price
$200/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
HIGHRequires Monitoring
YesNeeds lab work/checkups
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Dorzolamide in Glaucoma
Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
NCT01527682COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Brescia, Italy +1 more
Started: Jul 1, 2009
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
NCT00832377COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Started: Apr 24, 2009
Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients
NCT02053298COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Leuven, Belgium
Started: Jan 1, 2014
Circadian Rhythms of Aqueous Humor Dynamics in Humans
NCT00572936COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Omaha, United States
Started: Mar 13, 2006
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
NCT00449956COMPLETEDPHASE3
474 participants
INTERVENTIONAL
Started: Mar 12, 2007
Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses
NCT02852057COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Gainesville, United States
Started: Jan 18, 2018
Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety
NCT05857267COMPLETEDPHASE4
84 participants
INTERVENTIONAL
Olivos, Argentina +5 more
Started: Mar 7, 2023
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
NCT00546286COMPLETEDPHASE3
170 participants
INTERVENTIONAL
Started: May 31, 2006
Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
NCT01175902COMPLETEDNA
44 participants
INTERVENTIONAL
Seoul, South Korea
Started: Mar 1, 2011
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
NCT05973305COMPLETEDPHASE3
118 participants
INTERVENTIONAL
Kazan', Russia
Started: Apr 5, 2017
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
NCT00869141COMPLETEDPHASE4
52 participants
INTERVENTIONAL
Los Angeles, United States
Started: Mar 1, 2009
Pupillary Response After Glaucoma Medication
NCT02522039COMPLETEDNA
21 participants
INTERVENTIONAL
Glostrup Municipality, Denmark
Started: May 1, 2014
A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
NCT00991822COMPLETEDPHASE2, PHASE3
160 participants
INTERVENTIONAL
Vienna, Austria
Started: May 1, 1999
Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
NCT01062971COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Montemorelos, Mexico
Started: Feb 1, 2006
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
NCT00348400COMPLETEDPHASE4
INTERVENTIONAL
Pittsburgh, United States
12-Month Stability of Diurnal IOP Control on Cosopt
NCT00379834COMPLETEDPHASE4
10 participants
INTERVENTIONAL
Started: Sep 1, 2006
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
NCT00545064COMPLETEDPHASE4
176 participants
INTERVENTIONAL
Started: May 23, 2007
Showing 20 of 79 total trials